Highlights and Quick Summary
- Annual 3Y Reveue Growth (CAGR) for 2021 was 14.69% (a -152.0% decrease from previous year)
- Annual 3Y Reveue Growth (CAGR) for 2020 was -28.25% (a -27.99% decrease from previous year)
- Annual 3Y Reveue Growth (CAGR) for 2019 was -39.23% (a 206.25% increase from previous year)
Visit stockrow.com/NVCN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical 3Y Reveue Growth (CAGR) of Neovasc Inc.
Most recent 3Y Reveue Growth (CAGR)of NVCN including historical data for past 10 years.Interactive Chart of 3Y Reveue Growth (CAGR) of Neovasc Inc.
Neovasc Inc. 3Y Reveue Growth (CAGR) for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | – | – | – | – | 14.69% |
| 2020 | – | – | – | – | -28.25% |
| 2019 | – | – | – | – | -39.23% |
| 2018 | – | – | – | – | -12.81% |
| 2017 | – | – | – | – | 39.37% |
| 2016 | – | – | – | – | 64.54% |
| 2015 | – | – | – | – | 81.27% |
| 2014 | – | – | – | – | 36.94% |
| 2013 | – | – | – | – | 6.25% |
| 2012 | – | – | – | – | -7.65% |
| 2011 | – | – | – | – | -28.51% |
Business Profile of Neovasc Inc.
Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.